Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Borderline Personality Disorder (BPD)

Ketamine for Borderline Personality Disorder (BPD)

4 papers and 2 clinical trials exploring ketamine as a treatment for borderline personality disorder (bpd).

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
Indication1.8% of adults globally.

Borderline Personality Disorder (BPD)

Research into psychedelic-assisted therapies for Borderline Personality Disorder (BPD) indicates promising potential, particularly with compounds such as ketamine and MDMA, which may enhance emotional processing and neuroplasticity. However, systematic exclusion of BPD patients from psychedelic trials has limited available data, highlighting the need for dedicated research in this area.

Full Borderline Personality Disorder (BPD) profile

Academic Research

4 papers
Paywallindividual

Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder

In a real‑world observational cohort of 66 patients with treatment‑resistant bipolar I/II depression, four sub‑anaesthetic intravenous ketamine infusions over two weeks produced statistically and clinically significant, progressive reductions in depressive symptoms, suicidality and anxiety (mean QIDS‑SR16 reduction 6.08; p<0.0001). Response and remission rates were 35% and 20% respectively, with generally good tolerability (4.5% treatment‑emergent hypomania, no mania or psychosis).

Published
March 5, 2023
Journal
Bipolar Disorders
Authors
Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., Chau, E. H., Sethi, A., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., McIntyre, R. S., Rosenblat, J. D.
Paywallindividual

A pilot randomized controlled trial of ketamine in Borderline Personality Disorder

This randomised controlled trial (n=22) is the first to study ketamine (35mg/70kg) in Borderline (BPD) in a placebo-controlled study. The study didn't report statistically significant differences between the ketamine and midazolam (active placebo) groups, though it did show a positive trend.

Published
February 17, 2023
Journal
Neuropsychopharmacology
Authors
Fineberg, S. K., Choi, E. Y., Shapiro-Thompson, R., Dhaliwal, K., Neustadter, E., Sakheim, M., Null, K., Trujillo-Diaz, D., Rondeau, J., Pittaro, G. F., Peters, J. R., Corlett, P. R., Krystal, J. H.
Paywallindividual

Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic

This retrospective analysis (n=100) of the effectiveness of ketamine (35mg/70kg) for borderline personality disorder (BPD) in those with treatment-resistant depression (TRD) finds that intravenous ketamine significantly reduces symptoms of depression, borderline personality, suicidality, and anxiety in patients with comorbid BPD and TRD. Both BPD-positive and BPD-negative groups showed significant improvements in the primary outcome measures, with no significant difference between groups.

Published
June 29, 2021
Journal
Psychiatry Research
Authors
Danayan, K., Chisamore, N., Rodrigues, N. B., Di Vincenzo, J. D., Meshkat, S., Doyle, Z., Mansur, R. B., Phan, L., Fancy, F., Chau, E. H., Tabassum, A., Kratiuk, K., Arekapudi, A., Teopiz, K. M., McIntyre, R. S., Rosenblat, J. D.
Open Accessindividual

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

This double-blind, placebo-controlled, randomised study (n=18) with those suffering from bipolar depression (BD; treatment-resistant) found that ketamine (35mg/70kg; 2x 2w apart) produced anti-depressant effects as measured on the MADRS scale. The effects were found immediately (40 minutes) and lasted up to three days.

Published
August 1, 2010
Journal
JAMA Psychiatry
Authors
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., Machado- Vieira, R., Manji, H. K., Zarate, C. A.

Clinical Trials

2 trials
Not yet recruitingPhase II

Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

This Phase II randomised, quadruple-masked trial (n=120) will study adults aged 18 to 70 years with borderline personality disorder, treatment-resistant major depressive disorder or bipolar disorder, and suicidal ideation, evaluating whether intravenous ketamine plus dialectical behavioural therapy (DBT) reduces suicidal ideation more rapidly and robustly than midazolam plus DBT. The main purpose is to assess change in suicidal ideation severity from baseline to Day 35 using the Modified Scale for Suicidal Ideation (MSSI). All participants will receive DBT for 6 months, starting before the infusions, with weekly individual sessions and the addition of weekly group sessions from Week 5. The experimental arm will receive six intravenous ketamine infusions over 1 month: the first two at 0.5 mg/kg over 40 minutes, infusions 3 and 4 flexibly dosed at 0.5 mg/kg to 0.75 mg/kg, and infusions 5 and 6 flexibly dosed at 0.5 mg/kg to 0.85 mg/kg. The comparator arm will receive six intravenous midazolam infusions over the same period: the first two at 0.02 mg/kg over 40 minutes, infusions 3 and 4 at 0.02 mg/kg to 0.03 mg/kg, and infusions 5 and 6 at 0.2 mg/kg to 0.035 mg/kg. Participants will also complete hospital visits, remote follow-up by call or videocall, and a range of mood, cognitive and behavioural assessments.

Started
June 1, 2026
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT07569198
Not yet recruitingPhase II

Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder: A Pilot Study (BorderKET)

Open-label, single-group Phase II pilot (n=38) testing two IV ketamine infusions (0.5 mg/kg each, 40 min, at H0 and H24) plus Good Psychiatric Management in adults with severe BPD; primary outcome at day 9 (BSL-23).

Started
November 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT07099534

Explore further

Search all Ketamine papers Search all Borderline Personality Disorder (BPD) trials Full Ketamine profile Full Borderline Personality Disorder (BPD) profile